Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYT-200 · 2 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| LYT-200 | DRUG | monoclonal antibody (mAb), targeting galectin-9 protein |
| Tislelizumab | DRUG | anti-PD-1 monoclonal antibody |
| Gemcitabine/nab-paclitaxel | DRUG | chemotherapy |
| Venetoclax | DRUG | Bcl-2 inhibitor |
| Azacitidine | DRUG | Hypomethylating agent |
| Decitabine | DRUG | Hypomethylating agent |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LYT-200 is an investigational small molecule being studied for the treatment of adult recurrent acute myeloid leukemia (AML) and relapsed/refractory, high-risk myelodysplastic syndrome (MDS). It is also being evaluated in patients with locally advanced or metastatic solid tumors, including pancreatic cancer, urothelial carcinoma, head and neck cancer, and colorectal cancer.
LYT-200 is being developed by PureTech Health plc, a biopharmaceutical company listed on the London Stock Exchange under the ticker PRTC. The company is conducting clinical trials to evaluate the safety and efficacy of LYT-200 in oncology indications.
LYT-200 is in Phase 1 clinical development. One Phase 1 study is currently recruiting patients with relapsed/refractory AML or high-risk MDS, and a Phase 1/Phase 2 study in solid tumors has been completed. The drug is investigational and has not been approved by regulatory authorities.
LYT-200 is being studied in two clinical trials. NCT05829226 is a Phase 1 study in patients with relapsed/refractory AML or high-risk MDS, currently recruiting with a target enrollment of 90 participants. NCT04666688 is a Phase 1/Phase 2 study of LYT-200 alone or with chemotherapy or tislelizumab in solid tumors, which has been completed.
Yes, LYT-200 is being evaluated in combination with chemotherapy or tislelizumab in patients with locally advanced or metastatic solid tumors. This combination study, NCT04666688, has been completed. The ongoing Phase 1 study in AML and MDS is testing LYT-200 as a single agent.